Morgan Stanley analyst Terence Flynn lowered the firm’s price target on BioNTech (BNTX) to $131 from $133 and keeps an Overweight rating on the shares. Ahead of Q3 earnings, the firm adjusted models for IQVIA trends as well as intra-quarter updates, the analyst tells investors in a preview for the biopharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE: Strategic AI Integration and Innovations Drive Buy Rating
- BioNTech Hosts Second AI Day to Showcase AI Integration
- BioNTech price target raised to $121 from $116 at JPMorgan
- CDC panel votes against requiring prescriptions for Covid shots, Bloomberg says
- Pfizer, BioNTech express dedication to making safe Covid vaccines